Suicide ideation will be measured using the Scale for Suicide Ideation, an empirically-supported self-report scale that assesses the intensity of suicide-related thoughts, urges, intentions, and behaviors. Scores range from 0 to 38, with higher scores indicating more severe suicide ideation.
Baseline (Pretreatment)
Group
Value
95% CI
Safety Plan
5.91
± 7.79
Crisis Response Plan
6.37
± 7.67
1 week
Group
Value
95% CI
Safety Plan
3.67
± 5.64
Crisis Response Plan
2.47
± 4.83
2 weeks
Group
Value
95% CI
Safety Plan
3.00
± 5.49
Crisis Response Plan
2.25
± 5.18
26 weeks
Group
Value
95% CI
Safety Plan
3.49
± 6.59
Crisis Response Plan
3.20
± 6.22
52 weeks
Group
Value
95% CI
Safety Plan
3.42
± 5.32
Crisis Response Plan
3.36
± 5.37
Percent With Follow-up Suicidal BehaviorsPrimary· 52 weeks
Percent of participants with one or more suicidal behaviors will be measured using the Self-Injurious Thoughts and Behaviors Interview-Revised, an empirically-supported self-report scale that assesses a range of self-injurious behaviors including suicide attempts, interrupted suicide attempts, preparatory behaviors, and non-suicidal self-injury during the 52 week follow-up. Suicidal behaviors will be coded with a binary variable indicating the presence or absence of any suicidal behavior during the study period.
Group
Value
95% CI
Safety Plan
4
Crisis Response Plan
3
Number of Follow-up Suicidal BehaviorsPrimary· 52 weeks
Number of suicidal behaviors will be measured using the Self-Injurious Thoughts and Behaviors Interview-Revised, an empirically-supported self-report scale that assesses a range of self-injurious behaviors including suicide attempts, interrupted suicide attempts, preparatory behaviors, and non-suicidal self-injury during the 52 week follow-up. Suicidal behaviors will be coded with a binary variable indicating the presence or absence of any suicidal behavior during the study period and then summed to calculate the total number of suicidal behaviors during the 52 week follow-up.
Change in PTSD symptom severity will be measured using the National Stressful Events Survey PTSD Short Scale. Scores range from 0 to 36, with higher scores indicating more severe PTSD symptoms.
Baseline (Pretreatment)
Group
Value
95% CI
Safety Plan
27.01
± 7.09
Crisis Response Plan
25.93
± 7.38
1 week
Group
Value
95% CI
Safety Plan
17.57
± 7.59
Crisis Response Plan
18.05
± 8.74
2 weeks
Group
Value
95% CI
Safety Plan
13.42
± 8.10
Crisis Response Plan
13.06
± 6.85
26 weeks
Group
Value
95% CI
Safety Plan
14.09
± 9.22
Crisis Response Plan
14.87
± 9.33
52 weeks
Group
Value
95% CI
Safety Plan
14.85
± 8.91
Crisis Response Plan
14.83
± 9.44
Sponsor's own description
The efficacy of cognitive processing therapy (CPT) for reducing the symptoms of posttraumatic stress disorder (PTSD) across populations including military personnel and veterans is well supported. CPT also contributes to significant and rapid reductions in suicide ideation among people diagnosed with PTSD, although available evidence suggests this effect decays over time. Studies also show that approximately 1 in 6 people who begin CPT without suicide ideation will subsequently report suicidal thoughts at some point during or soon after completing treatment. Research focused on improving CPT's effects on suicide risk is therefore warranted. The primary aim of this study is to determine if the integration of a crisis response plan (CRP)--an empirically-supported procedure for reducing suicide ideation and attempts--can lead to faster reductions in suicide ideation among acutely suicidal veterans receiving CPT and prevent the development of suicide ideation among veterans who begin CPT without suicide ideation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University
Last refreshed: 20 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04690582.